Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | APEX1 | P27695 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15383092 | 1.00 | TDP1 (0.39) | TDP1MAPTTSHRMEN1LMNA | |
| SCHEMBL9964654 | 0.92 | MAPT (0.40) | TDP1MAPTTSHRMEN1LMNA | |
| SCHEMBL24178357 | 0.91 | TDP1 (0.46) | TDP1MAPT | |
| SCHEMBL12262553 | 0.87 | MAPT (0.37) | TDP1MAPTTSHR | |
| SCHEMBL12262572 | 0.85 | MAPT (0.36) | TDP1MAPTTSHRMEN1LMNA | |
| SCHEMBL17194014 | 0.85 | MAPT (0.36) | TDP1MAPTTSHRMEN1LMNA | |
| SCHEMBL15383093 | 0.85 | MAPT (0.38) | TDP1MAPTTSHR | |
| SCHEMBL15441005 | 0.82 | MAPT (0.39) | TDP1MAPTTSHR | |
| SCHEMBL15780104 | 0.82 | MAPT (0.41) | TDP1MAPTTSHR | |
| SCHEMBL11986256 | 0.81 | MAPT (0.51) | TDP1MAPTTSHRMEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160264728-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2016-09-15 | — | — | US | disclosed |
| US-9376531-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-20150299386-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | SAUDI ARAMCO TECHNOLOGIES COMPANY (SA) | 2015-10-22 | — | — | US | disclosed |
| US-8921508-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140046008-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20130244864-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-8470956-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20130066044-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | NOVOMER, INC. (US) | 2013-03-14 | — | — | US | disclosed |
| US-8247520-B2 | Polycarbonate polyol compositions and methods | NOVOMER, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| US-20110230580-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | Novomer, Inc (US) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230580-A1 | POLYCARBONATE POLYOL COMPOSITIONS AND METHODS | PARG, PUF60, PICALM | TDP1 2850/4885MAPT 3045/4885TSHR 4872/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.